Introduction There are plausible biological mechanisms for how obesity may be involved in the development of inflammatory bowel disease (IBD) due to the pro-inflammatory cytokines synthesised by adipose tissue including TNF-a. The aim of this work was to conduct the first prospective cohort study of obesity in the aetiology of IBD. Methods The cohort consisted of 366 351 healthy men and women aged 30e74 years from centres in Europe (EPICdEuropean Prospective Investigation into Cancer) recruited between the years 1991 and 1998. At recruitment participants' weight, height and energy intake were measured and physical activity from questionnaires and their body mass index (BMI) calculated. The cohort was monitored to 2004 to identify those who developed Crohn's disease (CD) or ulcerative colitis (UC). Each diagnosis was medically confirmed via review of the medical notes. Each case was matched with four controls, for gender, age at recruitment and centre. BMI was divided into five categories. Conditional logistic regression was used to calculate OR and 95% CI adjusted for smoking. Results In the cohort, 102 participants developed incident CD (73% female, mean age of 55.9 years, SD¼11.0 years) and 213 participants developed incident UC (61% female, mean age of 57.5 years, SD¼10.8 years). There were no associations between the four higher categories of BMI and the development of CD (Trend¼1.00, 95% CI 0.79 to 1.27, p¼0.91) or UC (Trend¼1.03, 95% CI 0.83 to 1.29, p 0.76). Dividing BMI in two categories. Conclusion No associations were found between BMI and either CD or UC. Further studies are required to confirm these results. If confirmed then BMI does not need to be measured in future epidemiological studies of IBD.
Introduction Reports from specialist inflammatory bowel disease (IBD) units have demonstrated that allopurinol and low-dose thiopurine co-therapy is an effective treatment option in patients who have failed standard dose therapy. There is little experience however from the district general hospital (DGH) setting. Co-therapy was introduced in our unit in September 2010. Aim To evaluate the safety and therapeutic outcome of IBD patients treated with azathioprine and allopurinol co-therapy at our institution. Methods A prospective database of all patients treated with allopurinol co-therapy is maintained at our institution. We reviewed the database entries and case notes of all patients. Data from patients who had been on allopurinol for <3 months were disregarded. Results 25 patients were identified, five were excluded because of insufficient follow-up (<3 months) and one patient was lost to follow-up. The median length of co-therapy was 9 (range 3e12) months. Diagnosis was ulcerative colitis (12), Crohn's disease (7), IBD-Unclassified (1). Indications for co-therapy were abnormal LFTs (3), drug side effects (8), high methylmercaptopurine (5), gout (2), therapeutic failure (2). 6-thioguanine nucleotide levels were measured where appropriate in patients before co-therapy, of these 50.0% were therapeutic. Following co-therapy 6-thioguanine nucleotide levels were therapeutic in 81.8% of patients. Co-therapy was effective and well tolerated in 13 (68.4%). Two (10%) patients developed side effects from allopurinol both had been treated with 200 mg od, in one patient (50%) symptoms resolved with dose reduction. Conclusion We have previously published our long-term outcome data of IBD patients treated with thiopurines; 55% of these patients stopped thiopurine therapy due to therapeutic failure or side effects. The current data demonstrate that the majority of this refractory
